Indication intelligence, analysis and sector perception

Fate Therapeutics (FATE) 5.2 M shares offering to raise $10.3 M in private placement priced at $1.96

August 8, 2016 8:51am

One key element, FATE did NOT use a placement agent in connection with the transaction. The purchase and sale is expected to close on or before August 10, 2016,

FATE has entered into a securities purchase agreement for a private placement with a select group of institutional investors, including funds managed by Franklin Advisers, Inc., under which the investors have agreed to purchase 5,250,000 shares of FATE’s common stock at a price of $1.96 per share, for gross proceeds of approximately $10.3 M.

FATE did not use a placement agent in connection with the transaction.

The purchase and sale is expected to close on or before 8/10/16, subject to customary closing conditions.

The Bottom Line: FATE has broken the “mold” of financing announcements. Usually upon the release of a pending offering or private placement, a stock will depreciate based on the discount and unfolding dilution. FATE had closed at $2.11 having announced a private placement at a price of $1.96 with a select group of institutional investors, including funds managed by Franklin Advisers, Inc.

One key element, FATE did NOT use a placement agent in connection with the transaction. The purchase and sale is expected to close on or before August 10, 2016,

The share pricing jumped +$0.47 or +22.55% to $2.60 by 3 pm on Monday

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 19 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.